SEARCH

Download Color Headshot

SCHOLARS

Scott Gottlieb

Senior Fellow

Research Areas

Pharmaceutical policy, cost of prescription drugs, Food and Drug Administration (FDA), Centers for Medicare & Medicaid Services (CMS), healthcare reform, political and clinical trends in medicine, and medical innovation

Contact

202-862-5829

Send Email

@ScottGottliebMD

Research Assistant

Shani Benezra

202-862-7157

Send Email

Media Request

Hannah Bowen

202.570.6533

Send Email

DOWNLOAD VCARD

Bio & Experience

Scott Gottlieb is a physician and senior fellow at the American Enterprise Institute (AEI) and previously served as the 23rd commissioner of the US Food and Drug Administration (FDA) from 2017 to 2019. At AEI, Dr. Gottlieb's work focuses on advancing public health, accelerating biomedical innovation, improving healthcare delivery, and shaping how artificial intelligence and other emerging technologies can be applied to clinical practice.

At the FDA, Dr. Gottlieb focused on drug pricing, medical product innovation, food safety, and tobacco and vaping regulation. He led efforts to streamline the approval process for drugs and medical devices, including overseeing the approval of the first gene therapy–based cancer treatments, while achieving record numbers of novel and generic drug approvals in 2017 and 2018. Dr. Gottlieb also advanced policies to combat opioid addiction, promoted competition through new pathways for complex generic medications, helped expand the FDA's Oncology Center of Excellence, and implemented the 21st Century Cures Act to accelerate medical product development. He is widely recognized for modernizing FDA regulatory policy and advancing market-based approaches to improving competition, innovation, and patient access across the healthcare system.

Previously, Dr. Gottlieb served as the FDA's deputy commissioner for medical and scientific affairs. Before that, he served as a senior adviser to the administrator of the Centers for Medicare & Medicaid Services, where he helped implement the Medicare prescription drug benefit.

A frequent congressional witness and nationally recognized public health commentator, Dr. Gottlieb is a contributor to the business cable network CNBC and he is a regular guest on CBS News's *Face the Nation*, where he has become one of the program's most frequent non-journalist guests, appearing more than 100 times. He is an editorial contributor to the *Journal of the American Medical Association*, and his commentary appears in *The Wall Street Journal*, *The Washington Post*, and *The New York Times*, among other publications.

Dr. Gottlieb wrote the *New York Times* bestselling book *Uncontrolled Spread: Why COVID-19 Crushed Us and How We Can Defeat the Next Pandemic* (2021) and is writing *The Miracle Century: Making Sense of the Cell Therapy Revolution*.

Fortune magazine recognized him as one of the "World's 50 Greatest Leaders," and *Time* magazine named him one of its "50 People Transforming Healthcare."

Dr. Gottlieb is an elected member of the National Academy of Medicine. He is also a partner at the venture capital firm New Enterprise Associates and serves on the boards of Pfizer, UnitedHealth Group, Illumina, and the Mount Sinai Health System. Dr. Gottlieb earned his medical degree from the Mount Sinai School of Medicine (now the Icahn School of Medicine at Mount Sinai), where he was awarded an honorary Doctor of Science degree in 2019. He completed his residency in internal medicine at Mount Sinai Hospital in New York. He holds a Bachelor of Arts in economics from Wesleyan University in Middletown, Connecticut, where he serves on the board of trustees, and he received the Distinguished Alumni Award in 2019 and was named an honorary Doctor of Science in 2021.

Experience

American Enterprise Institute: Resident Fellow, 2019–present; 2007–17; 2002–03

New Enterprise Associates: Special Partner, 2019—present; Venture Partner, 2007–17

Pfizer, Aetion, Tempus, Illumina: Member, Board of Directors, 2019–present

National Academy of Medicine: Member, 2018–present

Food and Drug Administration: Commissioner, 2017–19; Deputy Commissioner for Medical and Scientific Affairs, 2005–07; Director of Medical Policy Development, 2004; Senior Adviser to the Commissioner for Medical Technology, 2003–04

US Department of Health and Human Services: Member, Federal Health IT Policy Committee, 2013–17

Society for Hospitalist Medicine: Member, Public Policy Committee, 2011–17

New York University School of Medicine: Clinical Assistant Professor, 2011–17

Food and Drug Law Institute: Member, Editorial Advisory Board, *Food and Drug Policy Forum*, 2011–17

Value-Based Cancer Care: Editorial Board Member, 2009–17

Cancer Commons: Editorial Board Member, 2009–17

Leukemia and Lymphoma Society: Member, Policy Board, 2012–14

***British Medical Journal*:** Staff Writer, 1997–2005

Centers for Medicare & Medicaid Services: Senior Adviser to the Administrator, 2004

***Pulse* (American Medical Association):** Senior Editor, 1996–2001

Education

Residency in Internal Medicine, Mount Sinai Medical Center
MD, Mount Sinai School of Medicine
BA, economics, Wesleyan University

Latest Scholarship

All Commentary Research & Testimony Events Multimedia

PRESS

CBS News

Discussing New FDA Leadership, Food Safety, and New Developments in mRNA Cancer Therapy: Gottlieb on CBS' 'Face the Nation'

Senior Fellow Scott Gottlieb discusses new FDA leadership, food safety, and new developments in mRNA cancer therapy on CBS' 'Face the Nation.'

BY SCOTT GOTTLIEB ON 23 AUG 26

PRESS

CNBC

Discussing President Trump's executive order on the childhood vaccine schedule and concerns over food safety: Gottlieb on CNBC's 'Squawk Box'

Senior Fellow Scott Gottlieb discusses President Trump's executive order on the childhood vaccine schedule and concerns over food safety on CNBC's 'Squawk Box.'

BY SCOTT GOTTLIEB ON 12 AUG 26

PRESS

CNBC

Discussing the latest developments in the Cyclospora outbreak: Gottlieb on CNBC's 'Squawk Box'

PRESS

CBS News

Discussing the federal response to the Cyclospora outbreak, rising measles cases, and the risks of compounded

Senior Fellow Scott Gottlieb discusses the latest developments in the Cyclospora outbreak on CNBC's 'Squawk Box.'

BY SCOTT GOTTLIEB ON 27 JUL 26

peptides: Gottlieb on CBS' 'Face the Nation'

Senior Fellow Scott Gottlieb discusses the federal response to the Cyclospora outbreak, rising measles cases, and the risks of compounded peptides on CBS' 'Face the Nation.'

BY SCOTT GOTTLIEB ON 26 JUL 26

PRESS

Discussing the FDA's probe into the Cyclospora outbreak: Gottlieb on MS Now's 'Money, Power, Politics with Stephanie Ruhle'

Senior Fellow Scott Gottlieb discusses the FDA's probe into the Cyclospora outbreak on MS Now's 'Money, Power, Politics with Stephanie Ruhle.'

BY SCOTT GOTTLIEB ON 22 JUL 26

PRESS

CNBC

Discussing the Cyclospora outbreak, the FDA's response, and steps consumers can take to reduce their risk: Gottlieb on CNBC's 'Squawk Box'

Senior Fellow Scott Gottlieb discusses the Cyclospora outbreak linked to bagged lettuce, the FDA's response, and steps consumers can take to reduce their risk on CNBC's 'Squawk Box.'

BY SCOTT GOTTLIEB ON 21 JUL 26

Opportunity and Social Mobility

Science, Energy, and Environment

Technology and Innovation

Washington, DC 20036

Main Telephone: 202.862.5800

Economic Policy Studies

Economics

Healthcare

Agricultural Policy Studies

Foreign and Defense Policy Studies

National Defense

Middle East

Asia

Europe

Social, Cultural, and Constitutional Studies

Law and Constitution

Politics and Public Opinion

Society and Culture

DONATE SUBSCRIBE

© 2026 AMERICAN ENTERPRISE INSTITUTE | PRIVACY POLICY